Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wockhardt To Export 100 Million Sputnik Vaccines

News Comes Following Respectable Q3 Results For Indian Pharma Firm

Executive Summary

Indian pharmaceutical firm Wockhardt is set to export up to 100 million doses of the Russian COVID-19 vaccine Sputnik V, through a technology transfer agreement with the Gamaleya National Research Institute of Epidemiology and Microbiology.

You may also be interested in...

Wockhardt Expands UK Vaccines Unit With Serum Institute Deal

India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.

Sputnik COVID-19 Vaccine Caught Up In Sanctions On Russia Over Ukraine Invasion

As Russia intensifies its invasion of Ukraine with missile attacks and a convoy of armored vehicles, the funder and promoter of the country’s COVID-19 vaccine, Sputnik V, has found itself the subject of punitive international sanctions alongside Russia’s Central Bank.

US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings

The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines. 


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts